Risk of suicide during treatment with venlafaxine, citalopram, fluoxetine, and dothiepin: retrospective cohort study
- 12 December 2006
- Vol. 334 (7587) , 242
- https://doi.org/10.1136/bmj.39041.445104.be
Abstract
Objective To compare the risk of suicide in adults using the antidepressant venlafaxine compared with citalopram, fluoxetine, and dothiepin. Design Retrospective cohort study. Setting UK General Practice Research Database. Participants 219 088 patients, aged 18-89 years, who were prescribed venlafaxine, citalopram, fluoxetine, or dothiepin from 1995 to 2005. Main outcome measures Completed suicide and attempted suicide. Results Venlafaxine users had a higher burden of risk factors for suicide, including previous suicide attempts and proxies for severe depression or depression that was difficult to treat. In the analysis for completed suicides, unadjusted and adjusted hazard ratios for venlafaxine compared with citalopram were 2.44 (95% confidence interval 1.12 to 5.31) and 1.70 (0.76 to 3.80), for venlafaxine compared with fluoxetine were 2.85 (1.37 to 5.94) and 1.63 (0.74 to 3.59), and for venlafaxine compared with dothiepin were 2.54 (1.07 to 6.02) and 1.31 (0.53 to 3.25). Compared with other study drugs, venlafaxine was also associated with an increased risk of attempted suicide, but adjustment for measured confounders substantially reduced the hazard ratios. Conclusions Venlafaxine use was consistently associated with higher risk of suicide compared with citalopram, fluoxetine, and dothiepin. Venlafaxine users had a higher burden of suicide risk factors, however, and adjustment for measured confounders substantially reduced the excess risks. Since the secondary data used in this analysis allowed only indirect and partial measurements of potential confounders, it is possible that residual confounding explains much, if not all, of the observed excess risk.Keywords
This publication has 22 references indexed in Scilit:
- Antidepressants and the Risk of Suicidal BehaviorsJAMA, 2004
- Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished dataThe Lancet, 2004
- Suicide Rates in Clinical Trials of SSRIs, Other Antidepressants, and Placebo: Analysis of FDA ReportsAmerican Journal of Psychiatry, 2003
- Mortality of Cystic Fibrosis Patients Treated with Tobramycin Solution for InhalationEpidemiology, 2003
- Suicide Risk Following Child Sexual AbuseAcademic Pediatrics, 2001
- Suicide Risk in Placebo-Controlled Studies of Major DepressionAmerican Journal of Psychiatry, 2001
- Use of the UK General Practice Research Database for pharmacoepidemiologyBritish Journal of Clinical Pharmacology, 1998
- Channeling of Three Newly Introduced Antidepressants to Patients Not Responding Satisfactorily to Previous TreatmentJournal of Clinical Psychopharmacology, 1997
- Comparison of Frequencies of Suicidal Tendencies Among Patients Receiving Fluoxetine, Lofepramine, Mianserin, or TrazodonePharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 1992
- ESTIMATING AND CORRECTING FOR CONFOUNDER MISCLASSIFICATIONAmerican Journal of Epidemiology, 1989